Evidence map›Paper›PMID 40521625›Full record

ArticleProtein science : a publication of the Protein Society2025

Mitigating product inhibition in 2'-hydroxybiphenyl-2-sulfinate desulfinase (DszB) with synthetic glycosylation.

Junbao Liang, Yi Zheng, Valerie Vaissier Welborn

Abstract read
In one paragraph

Article in Protein science : a publication of the Protein Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Junbao LiangDepartment of Chemistry, Virginia Tech, Blacksburg, Virginia, USA.
Yi ZhengDepartment of Chemistry, Virginia Tech, Blacksburg, Virginia, USA.
Valerie Vaissier WelbornDepartment of Chemistry, Virginia Tech, Blacksburg, Virginia, USA.ORCID 0000-0003-0834-4441

Funding

American Chemical Society Petroleum Research Fund 66767-ND6
6 · The paper itself

Abstract

The combustion of sulfur-rich crude oil is toxic to the environment, making the removal of sulfur impurities a priority for the sustainable use of liquid fuels. Biodesulfurization via the 4S pathway is a promising approach due to its C-S bond cleavage specificity and mild operating conditions. However, biodesulfurization is not economically viable due to the slow turnover of 2'-hydroxybiphenyl-2-sulfinate desulfinase (DszB), an enzyme catalyzing the conversion of 2'-hydroxybiphenyl-2-sulfinate to 2-hydroxybiphenyl and sulfite. Previous studies have identified product inhibition as the limiting factor in DszB, whereby solvent-exposed protein loops obstruct the active site after substrate binding. This closed conformation is stabilized by hydrophobic interactions between the loops and the product. Here, we propose an artificial glycosylation strategy to mitigate product inhibition in DszB. We modeled glycated DszB in the apo, ligand-bound, and product-bound states with molecular dynamics based on the AMOEBA polarizable force field, and analyzed the chemical positioning of the reactant and product compared to the wild type (WT). We find that the addition of glucose on three Ser loop residues increases the interaction of the loops with water, overcoming the weaker product-loop interactions, and thereby enabling product release. Importantly, the enhanced flexibility of the loops was subtle enough to not heavily disrupt the chemical positioning of the reactant, which suggests that the rate acceleration would be similar to that of the WT.

Indexed as

Carbon-Sulfur LyasesCatalytic DomainGlycosylationMolecular Dynamics SimulationCarbon-Sulfur Lyases4S pathwayAMOEBADszBglycationmolecular dynamicspolarizable force field

Identifiers

PMID40521625
PMCPMC12168087

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.